Ali Health has launched its new AI product, "Hydrogen Ion," which has completed internal testing and is now available for download.

The product has entered the practical application stage, primarily targeting physicians in clinical and scientific research fields. "Hydrogen Ion" emphasizes its core capabilities of "low hallucination, high evidence-based" responses, with all answers traceable to authoritative sources, supporting one-click source verification to ensure reliability, and aims to be the AI assistant with the lowest hallucination rate in the medical field.

Previously, Ali Health's financial reports indicated that its self-developed large medical model is actively exploring applications in serious medical fields, striving to enhance the model's evidence-based AI capabilities in critical areas such as clinical decision-making and clinical research. The launch of "Hydrogen Ion" represents the first productized manifestation of this model's capabilities.

Feedback from physicians who participated in the internal testing suggests that "Hydrogen Ion" demonstrates high accuracy in evidence-based Q&A, evidence integration, and analytical summarization tasks. It is particularly well-suited to the habits of domestic doctors in intelligent retrieval and the review of Chinese and English literature within clinical and research contexts. Its product logic is similar to the internationally popular OpenEvidence but holds advantages in localized user experience.

Previously, Alibaba had deployed consumer-facing health services through Tongyi Qianwen and Ant's A-Fu. The application of AI in high-threshold, highly specialized serious medical scenarios is now being undertaken by Ali Health, which has over a decade of experience in the healthcare sector. With this launch, Alibaba's AI strategy in the healthcare field has achieved a complete "C+D" (Consumer + Doctor) layout.